Trial Profile
A Two-part, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of SENS-401 in Subjects With Severe or Profound Sudden Sensorineural Hearing Loss
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 14 Sep 2023
Price :
$35
*
At a glance
- Drugs Arazasetron (Primary)
- Indications Sensorineural hearing loss
- Focus Registrational; Therapeutic Use
- Acronyms AUDIBLE-S
- Sponsors Sensorion
- 15 Jun 2022 According to a Sensorion media release, results from this trial will be presented at the Inner Ear Disorder Therapeutics Summit, a scientific conference 2022.
- 17 Mar 2022 Results presented in a Sensorion media release.
- 28 Jan 2022 Status changed from active, no longer recruiting to completed.